NCT07791797 Supplementation Absorption Comparison
| NCT ID | NCT07791797 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | RDC Clinical Pty Ltd |
| Condition | Healthy Volunteer |
| Study Type | INTERVENTIONAL |
| Enrollment | 160 participants |
| Start Date | 2026-08-31 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 160 participants in total. It began in 2026-08-31 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this interventional study is to compare the absorption of supplements with and without absorption enhancing technology in healthy volunteers. We will be testing vitamin D3 and omega 3 in both males and females 18 years and older. Part A will comprise of two arms receiving a single dose of omega-3 supplement, and two arms who will receive vitamin D3 supplement daily for 7 days. Part B comprises of two arms who will receive vitamin D3 supplement daily for 6 weeks.
Eligibility Criteria
Part A: Inclusion Criteria: * Adults 18 years and older * Generally healthy * BMI 18.5-29.9 kg/m2 * Able to provide informed consent * Agree to not participate in another clinical trial while enrolled in this trial * Agree not to change current diet and/or exercise frequency or intensity during entire study period * Participant's ability to participate fully and comply with demands of the study including attendance at all scheduled blood collection time points Exclusion Criteria: * Have a serious illness e.g. mood disorders such as depression, anxiety or bipolar disorder, neurological disorders such as MS, kidney disease, liver disease or heart conditions * Have an unstable illness e.g. diabetes and thyroid gland dysfunction * Current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years * Significant change in diet in the past 1-month (e.g., removal of a food group or calorie restriction) * Active smokers, nicotine use or drug (prescription or illegal substances) abuse * Chronic past and/or current alcohol use (\>21 alcoholic drinks week) * Pregnant or lactating women * Allergic to any of the ingredients in enhanced or standard formula * Participants who are currently participating in any other clinical trial or who have participated in any other clinical trial during the past 1 month (excluding RDC Clinical trials) * Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion * Regular use within the past 4 weeks of supplements containing the trial product Part B: The above criteria apply, plus baseline serum 25(OH)D \<20.0 ng/mL (\<50.0 nm/L)
Contact & Investigator
David Briskey
PRINCIPAL INVESTIGATOR
RDC Clinical
Frequently Asked Questions
Who can join the NCT07791797 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Healthy Volunteer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07791797 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07791797 currently recruiting?
Yes, NCT07791797 is actively recruiting participants. Contact the research team at research@rdcglobal.com.au for enrollment information.
Where is the NCT07791797 trial being conducted?
This trial is being conducted at Fortitude Valley, Australia.
Who is sponsoring the NCT07791797 clinical trial?
NCT07791797 is sponsored by RDC Clinical Pty Ltd. The principal investigator is David Briskey at RDC Clinical. The trial plans to enroll 160 participants.